GCG and type 2 diabetes mellitus: Furthermore, CVOTs have documented the cardiovascular safety of the GLP-1 RA drug class in type 2 diabetes (Sattar et al., 2021); for some [dulaglutide (Gerstein et al., 2019), liraglutide (Marso et al., 2016) and semaglutide (Marso et al., 2017)], the CVOTs also confirmed a cardiovascular benefit and eventually led to the approved use of these GLP-1 RAs to reduce cardiovascular risk in people with type 2 diabetes and established CVD or at high cardiovascular risk (Honigberg et al., 2020).